| Title: |
A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis. |
| Authors: |
Migita, Rioko1 (AUTHOR), Kimoto, Yasutaka1 (AUTHOR), Hiura, Junki1 (AUTHOR), Okumura, Yuta1 (AUTHOR), Horiuchi, Takahiko1 (AUTHOR) |
| Source: |
Case Reports in Rheumatology. 3/29/2022, p1-5. 5p. |
| Subject Terms: |
*HEPATOCELLULAR carcinoma, *TUMOR markers, *BLOOD testing, *BARICITINIB, *JOINT pain |
| Abstract: |
We report a case of rapidly progressing hepatocellular carcinoma after administration of Janus kinase (JAK) inhibitors to treat rheumatoid arthritis. A 76-year-old man was referred to our Department for pain in multiple joints and was diagnosed with rheumatoid arthritis. Blood tests revealed elevated hepatobiliary enzymes, but various tests revealed no signs suggestive of malignancy. He took baricitinib for 2 months followed by tofacitinib for 4 months. After that, he was diagnosed with hepatocellular carcinoma based on imaging findings and elevated tumor markers. This case showed the possibility of a causal relationship between JAK inhibitors and malignancy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Case Reports in Rheumatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
